How Can Vaccines Against Influenza and Other Viral Diseases Be Made More Effective?-Reference-Cited by-同舟云学术

How Can Vaccines Against Influenza and Other Viral Diseases Be Made More Effective?

Published:2010-12-21 Issue:12 Volume:8 Page:e1000571
ISSN:1545-7885
Container-title:PLoS Biology
language:en
Short-container-title:PLoS Biol

Author:

Nara Peter L.,Tobin Gregory J.,Chaudhuri A. Ray,Trujillo Jessie D.,Lin George,Cho Michael W.,Levin Simon A.,Ndifon Wilfred,Wingreen Ned S.

Publisher

Public Library of Science (PLoS)

Subject

General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Reference21 articles.

1. Clonal antibody dominance in HIV-1 infection: Cause for a limited and failing immune response.;H Kohler;J Acquir Immune Defic Syndr,1992

2. Deceptive imprinting in the immune response against HIV-1.;H Kohler;Immunol Today,1994

3. Deceptive imprinting and immune refocusing in vaccine design.;G Tobin;Vaccine,2008

4. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines.;W Ndifon;Proc Natl Acad Sci,2009

5. Positive selection on the H3 hemagglutinin gene of human influenza virus A.;R. M Bush;Mol Biol Evol,1999

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS‐CoV‐2 Omicron variants;Journal of Medical Virology;2024-08-28

2. Antigenic cooperation in viral populations: Transformation of functions of intra-host viral variants;Journal of Theoretical Biology;2024-03

3. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants;Frontiers in Immunology;2021-12-02

4. Glycan-masking spike antigen in NTD and RBD elicits broadly neutralizing antibodies against SARS-CoV-2 variants;2021-11-02

5. Targeted Alteration of Antibody-Based Immunodominance Enhances the Heterosubtypic Immunity of an Experimental PCV2 Vaccine;Vaccines;2020-09-04